The influence of lamivudine therapy on the course of chronic hepatitis B in renal allograft recipients
Lewandowska, D.; Durlik, M.; Pazik, J.; Lewandowski, Z.; Lao, M.ła.
Polski Merkuriusz Lekarski Organ Polskiego Towarzystwa Lekarskiego 15(88): 367-370
2003
ISSN/ISBN: 1426-9686 PMID: 14974368 Document Number: 564702
The aim of this study was to evaluate efficacy and safety of lamivudine therapy in renal allograft recipients with chronic hepatitis B infection. Twenty-four patients with chronic hepatitis B after renal transplantation were observed. We obtained HBV replication blockage in 95% of patients, in half of them also ALT normalisation was observed. Delayed HBV replication blockage was observed in patients with prolonged duration of haemodialysotherapy or HBV infection and HCV coinfection, although listed parameters did not influence overall treatment efficacy. After lamivudine discontinuation HBV replication relapsed, in part of patients with ALT activity elevation. We did not observed any serious adverse reactions under lamivudine therapy.